drugset / Trial / NCT06946589

Cardiac Changes After Effective Dose Carbetocin for Elective Caesarian Section

NCT06946589

Phase 4 Not yet recruiting 200 enrolled Jordan Leitch
RandomizedParallel-groupDouble-blindTreatment

Summary

The goal of this project is to examine the cardiac symptoms and physiologic changes after administration of a reduced dose of carbetocin in participants undergoing elective cesarian section. * Does reduced dose carbetocin (50mcg) have fewer cardiac side effects than usual dose carbetocin (100mcg) when comparing patient reported symptoms, ECG changes and troponin increases? * Is there a relationship between patient reported cardiac symptoms after carbetocin administration and subjective measures of cardiac ischemia (ECG changes and troponin increases? Researchers will compare 50mcg of carbetocin to the control group of 100mcg of carbetocin in patients undergoing elective cesarian section. Participants will: * Be given 50mcg or 100mcg of carbetocin during cesarian section * Asked to report cardiac symptoms * Be assessed for ECG changes and blood loss using standard of practice monitoring * Have a troponin I blood test completed after delivery

Timeline

Start
2025-08-01
Primary completion
2026-08-01
Completion
2027-09-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Carbetocin Peptide 50 ug
Subject Carbetocin Peptide 100 ug

Indications